Compare FEBO & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FEBO | GDTC |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | Hong Kong | Singapore |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 12.4M |
| IPO Year | 2022 | 2021 |
| Metric | FEBO | GDTC |
|---|---|---|
| Price | $1.16 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 12.8K | 7.3K |
| Earning Date | 04-30-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $0.73 |
| 52 Week High | $1.48 | $3.68 |
| Indicator | FEBO | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 48.51 | 44.44 |
| Support Level | $1.08 | $0.97 |
| Resistance Level | $1.16 | $1.11 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 16.67 | 52.03 |
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.